Subscribe
shutterstock_446090386_cristian_gusa
Cristian Gusa / Shutterstock.com
30 January 2024BiotechnologyMarisa Woutersen

Force pharma companies to provide drugs for rare cancer trials, UK govt told

MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Big Pharma
Novartis ends eight-year cancer drug dispute for $182m
7 December 2023   Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.
Americas
Cancer specialist to pay $83.4m over DNA sequencing infringement
16 November 2023   TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.


Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024

Editor's picks

Americas
Trump’s return sparks calls for pro-patent agenda
5 December 2024
Americas
Comparing life sciences IP in Brazil and the US
28 November 2024
Americas
UPC bans Meril Life Sciences from selling infringing heart valve
19 November 2024
Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Americas
Big Pharma counsel embrace AI but data and legal risks loom
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024

More on this story

Big Pharma
Novartis ends eight-year cancer drug dispute for $182m
7 December 2023   Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.
Americas
Cancer specialist to pay $83.4m over DNA sequencing infringement
16 November 2023   TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.

More on this story

Big Pharma
Novartis ends eight-year cancer drug dispute for $182m
7 December 2023   Case dismissed with settlement between Novartis and Daiichi Sankyo unit | Melanoma therapy at centre of feud after Novartis faced infringement claims over Tafinlar.
Americas
Cancer specialist to pay $83.4m over DNA sequencing infringement
16 November 2023   TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.

More features

Novartis shields eye-drop patent at European Patent Office
LSPN launches its first-ever US awards to celebrate life sciences leaders
Pharma giants seek closure on COVID-19 vaccine rows
How Inhibrx defended a $450m damages suit
Foley & Lardner adds litigation and transaction expert in New York
UPC deals further blow to Dexcom in glucose monitor dispute with Abbott
‘A marathon and a sprint at the same time’: How we won $452m damages
Judge denies Intellia bid to throw out suit over $100m Regeneron pact